BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results
Globenewswire·2026-03-24 20:05
POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial and Business Highlights Generated net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97%Completed the acquisition of the BioTissue H ...